Abstract
Treatment of phenylketonuria involves a restriction in the intake of natural proteins. This can lead to growth impairment. Weight, height and body mass index of 109 hyperphenylalaninemic patients (mild hyperphenylalaninemia (HPA) and phenylketonuria (PKU)) were determined from birth until 18 years, every 6 months, and differences to the healthy population, depending on the age, sex and phenotype, were analyzed. Data collection was longitudinal retrospective during 31 years. Statistical analysis of z-score values was performed by advanced statistical tools. Long-term evolution of anthropometric z-scores showed no significant statistical differences between PKU and mild HPA individuals, according to the general population. For PKU individuals, height is slightly lower and weight slightly higher than in the healthy population, but differences are smaller than one standard deviation. Nevertheless, over-time evolutions of female height z-scores are different in each type of pathology, with a crossover between 8 and 12 years (p = 0.0186).
Conclusions: It is nowadays possible to achieve a long-term normal growth in PKU patients with appropriate dietary treatment. There is however an acceleration of growth up to 8 years old for PKU female patients that leads to a slightly lower final height. Detection of this behaviour was possible by using nonlinear mixed effects models.
Similar content being viewed by others
Abbreviations
- BH4:
-
6R-5,6,7,8-tetrahydrobiopterin
- BMI:
-
Body mass index
- HPA:
-
Hyperphenylalaninemia
- MHPA:
-
Mild hyperphenylalaninemia
- Phe:
-
Phenylalanine
- PKU:
-
Phenylketonuria
- RDA:
-
Recommended dietary allowances
References
Acosta PB, Yannicelli S, Singh R, Mofidi S, Steiner R, De Vincentis E, Jurecki E, Bernstein L, Gleason S, Chetty M, Rouse B (2003) Nutrient intakes and physical growth of children with phenylketonuria undergoing nutrition therapy. J Am Diet Assoc 103:1167–73
Ahring K, Bélanger-Quintana A, Dokoupil K, Gokmen Ozel H, Lammardo AM, MacDonald A, Motzfeldt K, Nowacka M, Robert M, van Rijn M (2009) Dietary management practices in phenylketonuria across European centres. Clin Nutr 28:231–6
Aldámiz-Echevarría L, Bueno MA, Couce ML, Lage S, Dalmau J, Vitoria I, Andrade F, Blasco J, Alcalde C, Gil D, García MC, González-Lamuño D, Ruiz M, Peña-Quintana L, Ruiz MA, González D, Sánchez-Valverde F (2013) Anthropometric characteristics and nutrition in a cohort of PAH-deficient patients. Clin, Nutr Sep. doi:10.1016/j.clnu.2013.09.011, 26
Barash FF, Cheung CC, Weigle DS, Ren H, Kabigkting EB, Kuijper JL, Clifton DK, Steiner RA (1996) Leptin is a metabolic signal to the reproductive system. Endocrinology 137:3144–47
Belanger-Quintana A, Martínez-Pardo M (2011) Physical development in patients with phenylketonuria on dietary treatment: a retrospective study. Mol Genet Metab 104:480–4
Blau N, Bélanger-Quintana A, Demirkol M, Feillet F, Giovannini M, MacDonald A, Trefz FK, van Spronsen F, European PKU Centers (2010) Management of phenylketonuria in Europe: survey results from 19 countries. Mol Genet Metab 99:109–15
Blau N, van Spronsen FJ, Levy HL (2010) Phenylketonuria. Lancet 376:1417–27
Boepple PA, Mansfield MJ, Wierman ME, Rudlin CR, Bode HH, Crigler JF, Crawford JD, Crowley WF (1986) Use of a potent, long acting agonist of gonadotropin-releasing hormone in the treatment of precocious puberty. Endocr Rev 7:24–33
Bóveda MD, Couce ML, Castiñeiras DE, Cocho JA, Pérez B, Ugarte M, Fraga JM (2007) The tetrahydrobiopterin loading test in 36 patients with hyperphenylalaninaemia: evaluation of response and subsequent treatment. J Inherit Metab Dis 30:8–12
Burlina A, Blau N (2009) Effect of BH(4) supplementation on phenylalanine tolerance. J Inherit Metab Dis 32:40–45
Büyükgebiz B, Eroglu Y, Büy Ukgebiz A (1994) True precocious puberty associated with phenylketonuria. J Pediatr Endocrin 7:361–3
Campistol J, Lambruschini N, Gómez-López L, Gutiérrez A, Fuste E, Vilaseca MA (2010) Hiperfenilalaninemias. In: Sanjurjo P, Baldellou A (eds) Diagnóstico y tratamiento de las enfermedades metabólicas hereditarias. Ergon, Majadahonda, pp 423–39
Carrascosa A, Fernández JM, Fernández C, Fernández A, López-Siguero JP, Sánchez E, Sobradillo B, Yeste D (2008) Estudios españoles de crecimiento. Nuevos patrones antropométricos. Endocrinol Nutr 55:484–506
Demirkol M, Giżewska M, Giovannini M, Walter J (2011) Follow up of phenylketonuria patients. Mol Genet Metab 104:S31–39
Dobbelaere D, Michaud L, Debrabander A, Vanderbecken S, Gottrand F, Turck D, Farriaux JP (2003) Evaluation of nutritional status and pathophysiology of growth retardation in patients with phenylketonuria. J Inherit Metab Dis 26:1–11
Dokoupil K, Gokmen-Ozel H, Lammardo AM, Motzfeldt K, Robert M, Rocha JC, van Rijn M, Ahring K, Bélanger-Quintana A, MacDonald A (2012) Optimising growth in phenylketonuria: current state of the clinical evidence base. Clin Nutr 31:16–21
Durban M, Harezlak J, Wand MP, Carroll RJ (2005) Simple fitting of subject-specific curves for longitudinal data. Stat Med 24:1153–67
Enns GM, Koch R, Brumm V, Blakely E, Suter R, Jurecki E (2010) Suboptimal outcomes in patients with PKU treated early with diet alone: revisiting the evidence. Mol Genet Metab 101:99–109
Feillet F, Agostoni C (2010) Nutritional issues in treating phenylketonuria. J Inherit Metab Dis 33:659–64
Giovannini M, Verduci E, Salvatici E, Fiori L, Riva E (2006) Phenylketonuria: dietary and therapeutic challenges. J Inherit Metab Dis 30:145–52
Hoeksma M, Van Rijn M, Verkerk PH, Bosch AM, Mulder MF, de Klerk JB, de Koning TJ, Rubio-Gozalbo E, de Vries M, Sauer PJ, van Spronsen FJ (2005) The intake of total protein, natural protein and protein substitute and growth of height and head circumference in Dutch infants with phenylketonuria. J Inherit Metab Dis 28:845–54
Huemer M, Huemer C, Möslinger D, Huter D, Stöckler-Ipsirogluet S (2007) Growth and body composition in children with classical phenylketonuria: results in 34 patients and review of the literature. J Inherit Metab Dis 30:694–9
Lee D-J (2010) Smoothing mixed models for spatial and spatio-temporal data. Ph. D
Macleod EL, Ney DM (2010) Nutritional management of phenylketonuria. Ann Nestle Eng 68:58–69
Martínez-Pardo M, Marchante C, Dalmau J, Pérez M, Bellón C (1998) Protocolo de diagnóstico, tratamiento y seguimiento de las hiperfenilalaninemias. An Esp Pediatr 114:3–8
Palmaert MR, Radovick S, Boepple PA (1998) Leptin levels in children with central precociouos puberty. J Clin Endocrinol Metab 83:2260–65
Pinheiro J, Bates D, Debroy, Sarhar D. Linear and nonlinear mixed effects models. R package version 3.1-100. 2011.
Scaglioni S, Verduci E, Fiori L, Lammardo AM, Rossi S, Radaelli G, Riva E, Giovannini M (2004) Body mass index rebound and overweight at 8 years of age in hyperphenylalaninaemic children. Acta Paediatr 93:1596–600
Scheipl F, Greven S, Kuchenhoff H (2008) Size and power of tests for a zero random effect variance or polynomial regression in additive and linear mixed models. Comput Stat Data Anal 52:3283–99
Scheipl F (2010) RLRsim: exact (Restricted) Likelihood ratio tests for mixed and additive models. R package version 2.1-3.2014.
Singh RH, Quirk ME, Douglas TD, Brauchla MC (2010) BH(4) therapy impacts the nutrition status and intake in children with phenylketonuria: 2-year follow-up. J Inherit Metab Dis 33:689–95
Sorian L, Blanco M, Cortés M, Martínez C (2008) Tendencia secular de la edad de la menarquia en adolescentes españolas. Med Clin 131:20
Van der Schot LW, Doesburg WH, Sengers RC (1994) The phenylalanine response curve in relation to growth and mental development in the first year of life. Acta Paediatr 407:S68–S9
Van Spronsen FJ, Ahring KK, Gizewska M (2009) PKU-what is daily practice in various centres in Europe? Data from a questionnaire by the scientific advisory committee of the European Society of Phenylketonuria and Allied Disorders. J Inherit Metab Dis 32:58–64
Verkerk PH, van Spronsen FJ, Smit GP, Sengers RC (1994) Impaired prenatal and postnatal growth in Dutch patients with phenylketonuria. The National PKU Steering Committee. Arch Dis Child 71:114–18
Vockley J, Andersson HC, Andersson HC, Antshei KM, Braveman NE, Burton BK, Mitchell J, Smith WE, Thompson BH, Berry SA (2014) Phenylalanine hydroxylase deficiency: diagnosis and management guideline. Genet Med 16:188–200
Acknowledgments
The authors are very grateful to all the patients and their families for kindly participating in the study.
Conflict of interest
None of the authors have any conflicts of interest to declare. The research has not received external funding from any public or private institutions.
Author information
Authors and Affiliations
Corresponding author
Additional information
Communicated by Beat Steinmann
Rights and permissions
About this article
Cite this article
Couce, M.L., Guler, I., Anca-Couce, A. et al. New insights in growth of phenylketonuric patients. Eur J Pediatr 174, 651–659 (2015). https://doi.org/10.1007/s00431-014-2446-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00431-014-2446-8